Action Pharma A/S (Copenhagen, Denmark) was dedicated to the discovery and development of novel drugs based on the Melanocortin receptor target.
The core therapeutic focus was organ protection in severe cardiovascular diseases such as myocardial infarction, and post-surgical organ dysfunction as well as obesity, Type II diabetes, and inflammatory diseases,
In May 2012, Action Pharma’s lead compound AP214 was acquired by Abbott for USD 110 million in upfront payment. AP214 was in clinical phase II development in patients with increased risk of acute kidney injury associated with major cardiac surgery.
For more information, please contact:
Phone: +45 2481 6967